A Clinical Study of Rozanolixizumab in Patients with Chronic
Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
My CIDP CHOICE Clinical Study
Clinical research studies are scientific evaluations in people, led by researchers and
physicians. They can help advance the understanding of a disease and are the most
important way for researchers to find out if potential new treatments are safe and
effective. Studies like these are needed to be able to make new treatments available to
The international My CIDP CHOICE study is currently enrolling CIDP patients to help us
understand how effective and safe a new investigational drug, called rozanolixizumab, is
for the treatment of CIDP. Rozanolixizumab is a non-blood product and aims at lowering
the levels of immunoglobulins (IgG – a type of blood protein) in the body, including IgG
IgG that are thought to be linked to CIDP.
At the beginning of the My CIDP CHOICE study, the study participant’s Ig treatment will
be replaced by the study treatment (either rozanolixizumab or placebo). It will be given
as a subcutaneous (under the skin) infusion. Study participants will have an equal
chance of being assigned to rozanolixizumab or placebo. A placebo looks exactly like
the investigational drug, but it contains no medicinally active ingredients. In case the
study treatment does not work for the study participant, Ig treatment will immediately be
prescribed again (without waiting for the end of the study) by your study doctor.
About the Study
The study is looking to enroll a total of approximately 34 participants at approximately 24
study sites globally. The My CIDP CHOICE study will last for about 28 weeks (up to a
maximum of 40 weeks) for every participant. Some study visits may be conducted at
home. Participants for whom the study treatment works well may be able to enroll in a 6-
month follow-up study where everyone receives rozanolixizumab (no placebo), provided
they meet the entry criteria.
Patients interested in joining the My CIDP CHOICE study must:
• Be 18 years of age or older
• Have a definite or probable diagnosis of CIDP
• Have prior experience of discontinuing/reducing their immunoglobulin treatment
• Have been receiving immunoglobulin treatment with a stable dose for at least 4
You can find more information on clinicaltrials.gov if you search for the identifier
NCT03861481 or CIDP01 in the “Other terms” field.
If you are interested in participating, you can contact the clinic of Dr. Vera Bril (neurologist at Toronto General Hospital) by calling her study coordinator (Eduardo Ng) at 416-340-3898.